+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003)



Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003)



Euro Surveillance 10(2): 3-4



The use of NAT technology to screen blood donations in Italy became mandatory on 28 June 2002, but had been available experimentally since 2001. During the transition period, an EIA test to detect hepatitis C core antigen (HCVcoreAg) had also been permitted. Considering the large number of blood transfusion centres in Italy, an initial reorganisation of the biological validation of blood units was necessary, with a partial centralisation of NAT testing. The Gruppo Italiano per lo Studio delle Malattie Trasmissibili con la Trasfusione (Italian Group for the Study of Transfusion-Transmissible Diseases) conducted a national survey evaluating NAT testing, based on an annual collection of data through a questionnaire sent to all centres. In the first three years of the investigation, 219 blood transfusion centres returned the questionnaires. In the period between January 2001 and December 2003, 3 894 894 blood donations were investigated for HCV RNA and 2 186 468 for HIV RNA. Of these, 12 were found to be HCV RNA positive and four HIV RNA positive, with an observed NAT versus antibody-based assay yield of 3.1/106 donations for HCV and 1.8/106 donations for HIV, respectively. Five of the 12 HCV RNA positive and anti-HCV negative donors had abnormal ALT values and their donations would have been discarded even in absence of NAT testing. Thus the final NAT yield for HCV is 1.79/106. The residual risk for HCV or HIV transmission by blood transfusion after NAT implementation is currently estimated to be extremely low in Italy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 065223075

Download citation: RISBibTeXText

PMID: 29183496


Related references

Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveillance 10(2): 12-14, 2005

Screening of serologically negative plasma pools for hepatitis C virus by nucleic acid amplification testing in Croatia, 2001-2003. Transfusion and Apheresis Science 33(2): 175-179, 2005

The implementation of nucleic acid amplification technology testing for living tissue donors. Cell and Tissue Banking 11(2): 205-208, 2010

Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sanguinis 88(4): 289-303, 2005

Nucleic acid amplification technology screening for HBV DNA in Italy: routine application. Report on the first HBV DNA-positive HBsAG-negative donor. Transfusion Medicine 15(3): 251-253, 2005

Hepatitis B virus blood screening: impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen non-reactive window period and chronic infections. Vox Sanguinis 96(4): 292-297, 2009

Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes. Transfusion 59(1): 267-276, 2019

Multiplex amplification and separation of nucleic acid sequences using ligation-dependant strand displacement amplification and bioelectronic chip technology. Official Gazette of the United States Patent & Trademark Office Patents 1246(5), 2001

Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: analysis of 2003 data to inform 2004 decision making. Transfusion 44(11): 1547-1554, 2004

Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors Nucleic acid amplification testing and disease transmission. Transfusion (Bethesda) 40(2): 143-159, 2000

Population dynamics of Heteroptera and damage to hazelnuts in northern Latium Italy in 2001 - 2003 Dinamica di popolazione e rilavamento di danni causati alle nocciole da eterotteri nellalto Lazio nel triennio 2001 - 2003 Heteroptera. Frustula Entomologica. 2005- ; 28-2941-42: 188-200, 2006

Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Transfusion 45(8): 1242-1246, 2005

Years of scientific bird ringing on the island of Greifswalder Oie - noticeable observations and rediscoveries 2001-2003 10 Jahre wissenschaftliche Vogelberingung auf der Insel Greifswalder Oie - Bemerkenswerte Beobachtungen und Wiederfunde 2001-2003. Seevoegel. Juni; 242: 30-34, 2003

Detection of intracellular unimolecules using nucleic acid amplification technology. Tanpakushitsu Kakusan Koso. Protein Nucleic Acid Enzyme 49(17 Suppl): 2808-2812, 2004

New trends in nucleic acid based biosensors: University of Florence (Italy), 25-28 October 2003. Bioelectrochemistry 67(2): 131-133, 2005